| Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. | |
| | |
MedLine Citation:
|
PMID: 11156096 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Desmopressin (DDAVP) has been evaluated in many randomized clinical trials as a means to reduce blood loss and transfusion of allogeneic blood in cardiac operation requiring cardiopulmonary bypass. Desmopressin reduces blood loss in adult patients with excessive bleeding after cardiac operation. Its usefulness in patients undergoing complex congenital heart repair with cardiopulmonary bypass is unproved. METHODS: Sixty patients younger than 40 years of age scheduled for complex congenital heart operation (44 redo, 16 primary) were enrolled in this prospective, randomized, double-blind trial. Desmopressin 0.3 microg/kg or placebo was administered 10 minutes after protamine administration. Transfusion requirements and postoperative blood loss were recorded. Differences were analyzed using analysis of variance with a p value of 0.05 or less used to denote statistical significance. RESULTS: There were no differences in demographic or surgical characteristics between the DDAVP or placebo groups. There was no difference in blood loss and transfusion requirements between the DDAVP and placebo groups. During the intraoperative postinfusion time period, the median blood loss for redo patients was 343 versus 357 mL/m2 for placebo versus DDAVP, respectively, and for primary patients, the median blood loss was 277 versus 228 mL/m2. CONCLUSIONS: The prophylactic use of DDAVP to reduce excessive bleeding or transfusion requirements in patients undergoing complex congenital heart operations is not warranted. |
| | |
Authors:
|
W C Oliver; P J Santrach; G K Danielson; G A Nuttall; D R Schroeder; M H Ereth |
Related Documents
:
|
11167166 - On-site coagulation monitoring does not affect hemostatic outcome after cardiac surgery. 11847596 - Cardiopulmonary bypass copolymer surface modification reduces neither blood loss nor tr... 12118746 - Duroflo ii heparin bonding does not attenuate cytokine release or improve pulmonary fun... 1751106 - Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperativ... 9269706 - The long-term tolerability of enalapril in hypertensive patients with renal impairment. 23141906 - Initial clinical experience with the heartware left ventricular assist system: a single... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: The Annals of thoracic surgery Volume: 70 ISSN: 0003-4975 ISO Abbreviation: Ann. Thorac. Surg. Publication Date: 2000 Dec |
Date Detail:
|
Created Date: 2001-01-11 Completed Date: 2001-02-01 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 15030100R Medline TA: Ann Thorac Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 1923-30 Citation Subset: AIM; IM |
Affiliation:
|
Department of Anesthesiology, Mayo Foundation, Rochester, Minnesota 55905, USA. oliver.william@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Blood Coagulation Tests Blood Loss, Surgical / physiopathology, prevention & control* Blood Transfusion* Cardiopulmonary Bypass Child Child, Preschool Deamino Arginine Vasopressin / administration & dosage*, adverse effects Double-Blind Method Female Heart Defects, Congenital / surgery* Hemostasis, Surgical* Humans Infant Male Prospective Studies Reoperation |
| Chemical | |
Reg. No./Substance:
|
16679-58-6/Deamino Arginine Vasopressin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of pulmonary arteriovenous fistulas after bidirectional cavopulmonary shunt.
Next Document: DDD pacing mode survival in children with a dual-chamber pacemaker.